Latest development of approved COVID-19 drugs and COVID-19 drugs undergoing late stage clinical trials
As the world adapts to living with SARS-CoV-2, the continuous emergence of new variants has become a primary focus of current studies. In this review, we examined a range of available COVID-19 drugs, including FDA-regulated drugs and those undergoing late-stage clinical trials. Some FDA-regulated dr...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-12-01
|
| Series: | Frontiers in Drug Discovery |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fddsv.2023.1304129/full |
| _version_ | 1797434884368629760 |
|---|---|
| author | Bingru Feng Kai Fu |
| author_facet | Bingru Feng Kai Fu |
| author_sort | Bingru Feng |
| collection | DOAJ |
| description | As the world adapts to living with SARS-CoV-2, the continuous emergence of new variants has become a primary focus of current studies. In this review, we examined a range of available COVID-19 drugs, including FDA-regulated drugs and those undergoing late-stage clinical trials. Some FDA-regulated drugs, such as Veklury (remdesivir), Olumiant (baricitinib), and Actemra (tocilizumab), have garnered primary clinical status in treatment guidelines, supported by sufficient clinical evidence. Conversely, EUA-authorized therapies, such as some antiviral agents, have demonstrated lower efficacy due to the virus’s constant mutation. We also focused on COVID-19 drugs undergoing late-stage clinical trials, some of which have raised controversy in their administration, such as colchicine and corticosteroids, while others are worth exploring regarding their timing. Several ongoing multi-drug clinical trials are of particular interest, including the “MEDIC-LAUMC” trial that explores drug co-administration, and “ACTIV-2” and “ACTIV-3” trials that compare the effects of different drugs for non-hospitalized and hospitalized patients, respectively. These ongoing clinical trials at a late stage provide essential clinical evidence for future drug authorization and have the potential to provide better drug administration strategies for COVID-19 variants. We look forward to the continued exploration of drug co-administration, comprehensive clinical evidence for treatment, and the investigation of different potential drug utilization. |
| first_indexed | 2024-03-09T10:39:21Z |
| format | Article |
| id | doaj.art-20825c1506914cecb88602ad12760494 |
| institution | Directory Open Access Journal |
| issn | 2674-0338 |
| language | English |
| last_indexed | 2024-03-09T10:39:21Z |
| publishDate | 2023-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Drug Discovery |
| spelling | doaj.art-20825c1506914cecb88602ad127604942023-12-01T16:52:16ZengFrontiers Media S.A.Frontiers in Drug Discovery2674-03382023-12-01310.3389/fddsv.2023.13041291304129Latest development of approved COVID-19 drugs and COVID-19 drugs undergoing late stage clinical trialsBingru Feng0Kai Fu1Department of Bioengineering, George R. Brown School of Engineering, Rice University, Houston, TX, United StatesDepartment of Molecular, Cellular and Developmental Biology, University of California Los Angeles, Los Angeles, CA, United StatesAs the world adapts to living with SARS-CoV-2, the continuous emergence of new variants has become a primary focus of current studies. In this review, we examined a range of available COVID-19 drugs, including FDA-regulated drugs and those undergoing late-stage clinical trials. Some FDA-regulated drugs, such as Veklury (remdesivir), Olumiant (baricitinib), and Actemra (tocilizumab), have garnered primary clinical status in treatment guidelines, supported by sufficient clinical evidence. Conversely, EUA-authorized therapies, such as some antiviral agents, have demonstrated lower efficacy due to the virus’s constant mutation. We also focused on COVID-19 drugs undergoing late-stage clinical trials, some of which have raised controversy in their administration, such as colchicine and corticosteroids, while others are worth exploring regarding their timing. Several ongoing multi-drug clinical trials are of particular interest, including the “MEDIC-LAUMC” trial that explores drug co-administration, and “ACTIV-2” and “ACTIV-3” trials that compare the effects of different drugs for non-hospitalized and hospitalized patients, respectively. These ongoing clinical trials at a late stage provide essential clinical evidence for future drug authorization and have the potential to provide better drug administration strategies for COVID-19 variants. We look forward to the continued exploration of drug co-administration, comprehensive clinical evidence for treatment, and the investigation of different potential drug utilization.https://www.frontiersin.org/articles/10.3389/fddsv.2023.1304129/fullCOVID-19SARS-CoV-2drug administrationCOVID-19 clinical trialsFDA regulated drugs |
| spellingShingle | Bingru Feng Kai Fu Latest development of approved COVID-19 drugs and COVID-19 drugs undergoing late stage clinical trials Frontiers in Drug Discovery COVID-19 SARS-CoV-2 drug administration COVID-19 clinical trials FDA regulated drugs |
| title | Latest development of approved COVID-19 drugs and COVID-19 drugs undergoing late stage clinical trials |
| title_full | Latest development of approved COVID-19 drugs and COVID-19 drugs undergoing late stage clinical trials |
| title_fullStr | Latest development of approved COVID-19 drugs and COVID-19 drugs undergoing late stage clinical trials |
| title_full_unstemmed | Latest development of approved COVID-19 drugs and COVID-19 drugs undergoing late stage clinical trials |
| title_short | Latest development of approved COVID-19 drugs and COVID-19 drugs undergoing late stage clinical trials |
| title_sort | latest development of approved covid 19 drugs and covid 19 drugs undergoing late stage clinical trials |
| topic | COVID-19 SARS-CoV-2 drug administration COVID-19 clinical trials FDA regulated drugs |
| url | https://www.frontiersin.org/articles/10.3389/fddsv.2023.1304129/full |
| work_keys_str_mv | AT bingrufeng latestdevelopmentofapprovedcovid19drugsandcovid19drugsundergoinglatestageclinicaltrials AT kaifu latestdevelopmentofapprovedcovid19drugsandcovid19drugsundergoinglatestageclinicaltrials |